6 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... #Tuberculosis ... Therapy #regimens #medications ... #pharmacology # ... #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... Resistant Tuberculosis ... isolate DST result should ... antimicrobials #regimens #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... should be initiated ... #TB #IDSA #Prevention ... infections #HIVAIDS #pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... Patients should ... been shown non-inferior ... #semaglutide #Diabetes ... #Pharmacology #
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... Prophylaxis): Indications ... Note: Active TB should ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... ., concomitant medications ... should include ... intraocular levels of drug ... infections #HIVAIDS #pharmacology